1493 related articles for article (PubMed ID: 9571956)
1. Mangafodipir trisodium (MnDPDP)-enhanced magnetic resonance imaging of the liver and pancreas.
Wang C
Acta Radiol Suppl; 1998; 415():1-31. PubMed ID: 9571956
[TBL] [Abstract][Full Text] [Related]
2. Characterization of focal liver lesions: use of mangafodipir trisodium (MnDPDP)-enhanced MR images.
Karabacakoğlu A; Adigüzel Y; Karaköse S; Kayaçetin E; Haykir R
Turk J Gastroenterol; 2006 Sep; 17(3):164-71. PubMed ID: 16941248
[TBL] [Abstract][Full Text] [Related]
3. Pancreatic enhancement and pulse sequence analysis using low-dose mangafodipir trisodium.
Mayo-Smith WW; Schima W; Saini S; Slater GJ; McFarland EG
AJR Am J Roentgenol; 1998 Mar; 170(3):649-52. PubMed ID: 9490946
[TBL] [Abstract][Full Text] [Related]
4. Mangafodipir trisodium-enhanced magnetic resonance imaging for evaluation of pancreatic mass and mass-like lesions.
Eser G; Karabacakoglu A; Karakose S; Eser C; Kayacetin E
World J Gastroenterol; 2006 Mar; 12(10):1603-6. PubMed ID: 16570354
[TBL] [Abstract][Full Text] [Related]
5. Mangafodipir trisodium-enhanced MRI for the detection and characterization of focal hepatic lesions: is delayed imaging useful?
Chung JJ; Kim MJ; Kim KW
J Magn Reson Imaging; 2006 May; 23(5):706-11. PubMed ID: 16565954
[TBL] [Abstract][Full Text] [Related]
6. Tolerability and utility of mangafodipir trisodium injection (MnDPDP) at the dose of 5 mumol/kg body weight in detecting focal liver tumors: results of a phase III trial using an infusion technique.
Padovani B; Lecesne R; Raffaelli C; Chevallier P; Drouillard J; Bruneton JN; Lambrechts M; Gordon P
Eur J Radiol; 1996 Nov; 23(3):205-11. PubMed ID: 9003926
[TBL] [Abstract][Full Text] [Related]
7. Mn-DPDP in MR imaging of pancreatic adenocarcinoma: initial clinical experience.
Gehl HB; Urhahn R; Bohndorf K; Klever P; Hauptmann S; Lodemann KP; Matern S; Schumpelick V; Günther RW
Radiology; 1993 Mar; 186(3):795-8. PubMed ID: 8430190
[TBL] [Abstract][Full Text] [Related]
8. Characterization of hepatocellular tumors: value of mangafodipir-enhanced magnetic resonance imaging.
Scharitzer M; Schima W; Schober E; Reimer P; Helmberger TK; Holzknecht N; Stadler A; Ba-Ssalamah A; Weber M; Wrba F
J Comput Assist Tomogr; 2005; 29(2):181-90. PubMed ID: 15772534
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic accuracy of portal-phase CT and MRI with mangafodipir trisodium in detecting liver metastases from colorectal carcinoma.
Regge D; Campanella D; Anselmetti GC; Cirillo S; Gallo TM; Muratore A; Capussotti L; Galatola G; Floriani I; Aglietta M
Clin Radiol; 2006 Apr; 61(4):338-47. PubMed ID: 16546464
[TBL] [Abstract][Full Text] [Related]
10. Hepatocellular carcinoma: MR imaging with mangafodipir trisodium (Mn-DPDP).
Murakami T; Baron RL; Peterson MS; Oliver JH; Davis PL; Confer SR; Federle MP
Radiology; 1996 Jul; 200(1):69-77. PubMed ID: 8657947
[TBL] [Abstract][Full Text] [Related]
11. Detection of liver metastases from adenocarcinoma of the colon and pancreas: comparison of mangafodipir trisodium-enhanced liver MRI and whole-body FDG PET.
Sahani DV; Kalva SP; Fischman AJ; Kadavigere R; Blake M; Hahn PF; Saini S
AJR Am J Roentgenol; 2005 Jul; 185(1):239-46. PubMed ID: 15972430
[TBL] [Abstract][Full Text] [Related]
12. MnDPDP for MR imaging of the liver. Results of an independent image evaluation of the European phase III studies.
Rummeny EJ; Torres CG; Kurdziel JC; Nilsen G; Op de Beeck B; Lundby B
Acta Radiol; 1997 Jul; 38(4 Pt 2):638-42. PubMed ID: 9245957
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic efficacy of MnDPDP in MR imaging of the liver. A phase III multicentre study.
Wang C; Ahlström H; Ekholm S; Fagertun H; Hellström M; Hemmingsson A; Holtås S; Isberg B; Jonnson E; Lönnemark-Magnusson M; McGill S; Wallengren NO; Westman L
Acta Radiol; 1997 Jul; 38(4 Pt 2):643-9. PubMed ID: 9245958
[TBL] [Abstract][Full Text] [Related]
14. [Manganese-DPDP in the MR tomography of malignant liver tumors. The initial results with a new hepatobiliary contrast agent].
Steudel A; Layer G; Kraheck H; Hartlapp J; Reiser M
Rofo; 1992 May; 156(5):460-4. PubMed ID: 1596550
[TBL] [Abstract][Full Text] [Related]
15. Mangafodipir trisodium injection (Mn-DPDP). A contrast agent for abdominal MR imaging.
Rofsky NM; Earls JP
Magn Reson Imaging Clin N Am; 1996 Feb; 4(1):73-85. PubMed ID: 8673718
[TBL] [Abstract][Full Text] [Related]
16. Mangafodipir trisodium-enhanced MRI of hepatocellular carcinoma: correlation with histological characteristics.
Kim JH; Kim MJ; Park YN; Lee JT; Kim BR; Chung JB; Choi JS; Kim KS; Kim KW
Clin Radiol; 2008 Nov; 63(11):1195-204. PubMed ID: 18929037
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic accuracy of rim and segmental MRI enhancement of colorectal hepatic metastasis after administration of mangafodipir trisodium.
Koh DM; Brown G; Meer Z; Norman AR; Husband JE
AJR Am J Roentgenol; 2007 Feb; 188(2):W154-61. PubMed ID: 17242222
[TBL] [Abstract][Full Text] [Related]
18. Benign and malignant hepatocellular tumors: evaluation of tumoral enhancement after mangafodipir trisodium injection on MR imaging.
Coffin CM; Diche T; Mahfouz A; Alexandre M; Caseiro-Alves F; Rahmouni A; Vasile N; Mathieu D
Eur Radiol; 1999; 9(3):444-9. PubMed ID: 10087113
[TBL] [Abstract][Full Text] [Related]
19. Uptake of mangafodipir trisodium in liver metastases from endocrine tumors.
Wang C; Ahlström H; Eriksson B; Lönnemark M; McGill S; Hemmingsson A
J Magn Reson Imaging; 1998; 8(3):682-6. PubMed ID: 9626886
[TBL] [Abstract][Full Text] [Related]
20. MRI characteristics in focal hepatic disease before and after administration of MnDPDP: discriminant analysis as a diagnostic tool.
Helmberger TK; Laubenberger J; Rummeny E; Jung G; Sievers K; Döhring W; Meurer K; Reiser MF
Eur Radiol; 2002 Jan; 12(1):62-70. PubMed ID: 11868075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
